Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1674 1699
This examiner grants 56% of resolved cases
Sandra Dillahunt Carter is an examiner in Tech Center 1600 and Art Unit 1646. She has resolved 527 cases with an allowance rate of 56.2 percent. This rate indicates a balanced prosecution environment where a grant is achieved in a portion of cases. The 527 resolved cases offer a dataset for understanding the examiner's approach.
The interview lift is 29.0 percent, which is an increase over the 56.2 percent baseline. This suggests that interviews are effective at moving cases toward allowance. Practitioners should prioritize direct communication to leverage this 29.0 percent lift. The data implies that verbal discussion is a successful method for resolving issues that might otherwise lead to a rejection.
The median days to allowance is 1277. This figure represents the timeframe for reaching a positive conclusion in prosecution. While the 56.2 percent allowance rate is moderate, the 1277-day duration indicates that the process requires persistence. The 29.0 percent lift is a tool for applicants to use during this 1277-day period to improve their chances of success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18497169 | MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | Non-Final OA | ImmunityBio, Inc. |
| 18628097 | METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | Non-Final OA | Novartis AG |
| 17920942 | CD25-TARGETED IL-2 FOR INCREASING CD4 T CELL FORMATION AND TREATMENT OF INFECTIONS | Final Rejection | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. |
| 18246604 | METHODS AND COMPOSITIONS FOR IN SITU IMMUNE PROFILING OF HEART TRANSPLANT BIOPSIES | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17563392 | COMPOSITIONS, COMPRISING IMPROVED IL-12 GENETIC CONSTRUCTS AND VACCINES, IMMUNOTHERAPEUTICS AND METHODS OF USING THE SAME | Final Rejection | The Trustees of the University of Pennsylvania |
| 18000226 | ISOLATED PEPTIDE FOR A PEPTIDE COACERVATE, AND METHODS OF USE THEREOF | Non-Final OA | NANYANG TECHNOLOGICAL UNIVERSITY |
| 17908415 | PROTEIN NANOPARTICLE DESIGN AND APPLICATION | Final Rejection | Duke University |
| 18057709 | COMPOSITIONS OF ENGINEERED EXOSOMES AND METHODS OF LOADING LUMINAL EXOSOMES PAY-LOADS | Non-Final OA | LONZA SALES AG |
| 18706716 | PEPTIDE HAVING PHYSIOLOGICAL ACTIVITY AND USE THEREOF | Non-Final OA | CAREGEN CO., LTD. |
| 17815194 | IL-18-FC FUSION PROTEINS | Non-Final OA | Xencor, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy